---
title: "Vaccinex alerts on new press release availability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292068370.md"
description: "Vaccinex issued a press release detailing new biomarker results from its Phase 1b/2 SIGNAL-AD trial of pepinemab for early Alzheimer’s disease. The company also announced plans for an expanded randomized Phase 2B study, SIGNAL-AD2. These data and trial plans are scheduled to be presented at the Alzheimer’s Association International Conference in London on July 13, 2026."
datetime: "2026-07-08T12:31:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292068370.md)
  - [en](https://longbridge.com/en/news/292068370.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292068370.md)
generator: "portal-rs"
---

# Vaccinex alerts on new press release availability

-   Vaccinex posted a press release outlining new biomarker results from its Phase 1b/2 SIGNAL-AD trial of pepinemab in early Alzheimer’s disease. \* Release also set out plans for an enlarged randomized Phase 2B study, SIGNAL-AD2. \* Data and trial plans are slated for presentation at the Alzheimer’s Association International Conference in London on July 13, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaccinex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080830PRIMZONEFULLFEED9758948) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VCNX.US](https://longbridge.com/en/quote/VCNX.US.md)

## Related News & Research

- [Is Toast (TOST) Reasonable After Its 141% Three Year Run?](https://longbridge.com/en/news/305559209.md)
- [How Shelf Registration Will Impact Celldex Therapeutics (CLDX) Stock Investors](https://longbridge.com/en/news/305560069.md)
- [Hengrui Adds Three Drugs to China’s National Reimbursement List](https://longbridge.com/en/news/305569530.md)
- [Phase 3 Path Cleared Might Change The Case For Investing In Edgewise Therapeutics (EWTX)](https://longbridge.com/en/news/305561356.md)
- [Ameren (AEE) Could Be 2% Undervalued Following Earnings Beat And 2027 Outlook](https://longbridge.com/en/news/305560366.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**